

DAFTAR PUSTAKA

- [1] T. Löwenmark, *GUT MICROBIOTA IN COLORECTAL CANCER The importance of Parvimonas micra*. Sweden: Umea University, 2024.
- [2] H. Sung *et al.*, “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.
- [3] A. Cañellas-Socias, E. Sancho, and E. Batlle, “Mechanisms of metastatic colorectal cancer,” *Nat Rev Gastroenterol Hepatol*, vol. 21, pp. 609–625, 2024, [Online]. Available: 10.1038/s41575-024-00934-z. Epub 2024 May 28.
- [4] P. Zhou, D. Yang, D. Sun, and Y. Zhou, “Gut microbiome: New biomarkers in early screening of colorectal cancer,” *J. Clin. Lab. Anal.*, vol. 36, no. 5, pp. 1–7, 2022, doi: 10.1002/jcla.24359.
- [5] H. D. Purnomo *et al.*, “Colorectal cancer screening in Semarang, Indonesia: A multicenter primary health care based study,” *PLoS One*, vol. 18, no. 1 January, pp. 1–12, 2023, doi: 10.1371/journal.pone.0279570.
- [6] G. Roshandel, F. Ghasemi-Kebria, and R. Malekzadeh, “Colorectal Cancer: Epidemiology, Risk Factors, and Prevention,” *MDPI*, vol. 16, pp. 1–22, 2024, doi: [https://doi.org/ 10.3390/cancers16081530](https://doi.org/10.3390/cancers16081530).
- [7] P. Rawla, T. Sunkara, and A. Barsouk, “Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors,” *Prz. Gastroenterol.*, vol. 14, no. 2, pp. 89–103, 2019, doi: 10.5114/pg.2018.81072.
- [8] M. S. Hossain *et al.*, “Colorectal Cancer : A Review of Carcinogenesis , Global,” *Cancer*, vol. 14, no. 1732, pp. 1–25, 2022.
- [9] P. Wei *et al.*, “Microbiota in colorectal cancer related to liver metastasis,” *Chinese J. Cancer Res.*, vol. 36, no. 1, pp. 17–24, 2024, doi: 10.21147/j.issn.1000-9604.2024.01.02.
- [10] E. Biological and P. Of, “HHS Public Access,” vol. 168, no. 4, pp. 670–691,

2018, doi: 10.1016/j.cell.2016.11.037.EMERGING.

- [11] D. Lin *et al.*, “Circulating tumor cells : biology and clinical significance,” no. July, 2021, doi: 10.1038/s41392-021-00817-8.
- [12] M. S. Choene and L. R. Motadi, “Gene Reports Molecular mechanism of angiogenesis in colorectal cancer,” *Gene Reports*, vol. 39, no. February, p. 102163, 2025, doi: 10.1016/j.genrep.2025.102163.
- [13] S. Yu, S. Wang, B. Xiong, and C. Peng, “Gut microbiota: key facilitator in metastasis of colorectal cancer,” *Front. Oncol.*, vol. 13, no. October, pp. 1–11, 2023, doi: 10.3389/fonc.2023.1270991.
- [14] C. Zhang, Y. Wang, L. Cheng, X. Cao, and C. Liu, “Gut microbiota in colorectal cancer: a review of its influence on tumor immune surveillance and therapeutic response,” *Front. Oncol.*, vol. 15, no. March, pp. 1–15, 2025, doi: 10.3389/fonc.2025.1557959.
- [15] S. Cass and M. G. White, “The Influence of the Microbiome on Metastatic Colorectal Cancer,” *Clin. Colon Rectal Surg.*, vol. 36, no. 2, pp. 112–119, 2023, doi: 10.1055/s-0043-1760864.
- [16] H. Pandey, D. W. T. Tang, S. H. Wong, and D. Lal, “Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities,” *Cancers (Basel)*, vol. 15, no. 3, 2023, doi: 10.3390/cancers15030866.
- [17] O. O. Coker, W. K. K. Wu, S. H. Wong, J. J. Y. Sung, and J. Yu, “Altered Gut Archaea Composition and Interaction With Bacteria Are Associated With Colorectal Cancer,” *Gastroenterology*, vol. 159, no. 4, pp. 1459-1470.e5, 2020, doi: 10.1053/j.gastro.2020.06.042.
- [18] L. Sun *et al.*, “The difference of human gut microbiome in colorectal cancer with and without metastases,” *Front. Oncol.*, vol. 12, no. November, pp. 1–15, 2022, doi: 10.3389/fonc.2022.982744.
- [19] T. Matsuda, A. Fujimoto, and Y. Igarashi, “Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies,” *Digestion*, vol. 106, no. 2, pp. 91–99, 2025, doi: 10.1159/000543921.

- [20] X. Zhou *et al.*, “Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis,” *Int. J. Cancer*, vol. 151, no. 1, pp. 83–94, 2022, doi: 10.1002/ijc.33945.
- [21] T. Matsuda, A. Fujimoto, and Y. Igarashi, “Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies,” *Digestion*, pp. 91–99, 2025, doi: 10.1159/000543921.
- [22] T. Sawicki, M. Ruszkowska, A. Danielewicz, E. Niedźwiedzka, T. Arłukowicz, and K. E. Przybyłowicz, “A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis,” *Cancers (Basel)*, vol. 13, no. 9, pp. 1–23, 2021, doi: 10.3390/cancers13092025.
- [23] J. Madrigal-matute and S. Bañón-escandell, “Colorectal Cancer and Microbiota Modulation for Clinical Use . A Systematic Review,” *Nutr. Cancer*, vol. 0, no. 0, pp. 1–17, 2022, doi: 10.1080/01635581.2022.2108468.
- [24] S. Zahir Ahmed, N. Cirocchi, E. Saxton, and M. K. Brown, “Incidence of age migration of colorectal cancer in younger population: Retrospective single centred-population based cohort study,” *Ann. Med. Surg.*, vol. 74, no. November 2021, p. 103214, 2022, doi: 10.1016/j.amsu.2021.103214.
- [25] P. Dharwadkar, T. A. Zaki, and C. C. Murphy, “Colorectal Cancer in Younger Adults,” *Hematol. Oncol. Clin. North Am.*, vol. 36, no. 3, pp. 449–470, 2022, doi: 10.1016/j.hoc.2022.02.005.
- [26] M. Abancens, V. Bustos, H. Harvey, J. McBryan, and B. J. Harvey, “Sexual Dimorphism in Colon Cancer,” *Front. Oncol.*, vol. 10, no. December, pp. 1–27, 2020, doi: 10.3389/fonc.2020.607909.
- [27] Y. Cheng, Z. Ling, and L. Li, “The Intestinal Microbiota and Colorectal Cancer,” *Front. Immunol.*, vol. 11, no. November, pp. 1–13, 2020, doi: 10.3389/fimmu.2020.615056.
- [28] V. A. Ionescu *et al.*, “Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection,” *Int. J. Mol. Sci.*, vol. 26, no. 8, pp. 1–30, 2025,

doi: 10.3390/ijms26083733.

- [29] W. Ruan, M. A. Engevik, J. K. Spinler, and J. Versalovic, “Healthy Human Gastrointestinal Microbiome: Composition and Function After a Decade of Exploration,” *Dig. Dis. Sci.*, vol. 65, no. 3, pp. 695–705, 2020, doi: 10.1007/s10620-020-06118-4.
- [30] M. Rebersek, “Gut microbiome and its role in colorectal cancer,” *BMC Cancer*, vol. 21, no. 1, pp. 1–13, 2021, doi: 10.1186/s12885-021-09054-2.
- [31] N. Hasan and H. Yang, “Factors affecting the composition of the gut microbiota, and its modulation,” *PeerJ*, vol. 2019, no. 8, pp. 1–31, 2019, doi: 10.7717/peerj.7502.
- [32] Y. Fan and O. Pedersen, “Gut microbiota in human metabolic health and disease,” *Nat. Rev. Microbiol.*, vol. 19, no. 1, pp. 55–71, 2021, doi: 10.1038/s41579-020-0433-9.
- [33] E. S. Rahayu *et al.*, “Gut microbiota profile in healthy Indonesians,” *World J. Gastroenterol.*, vol. 25, no. 12, pp. 1478–1491, 2019, doi: 10.3748/wjg.v25.i12.1478.
- [34] N. Darnindro, M. Abdullah, and N. L. Sukartini, “Composition and Diversity of Intestinal Microbiota in Colorectal Cancer and Potential Utilization in Diagnosis and Therapy,” vol. 25, no. 2, pp. 247–253.
- [35] Z. Chilimoniuk *et al.*, “Correlation between gut microbiota dysbiosis and colorectal cancer: review,” *Licens. Open J. Syst. Nicolaus Copernicus Univ.*, pp. 1–20, 2024, doi: <https://dx.doi.org/10.12775/QS.2024.22.54326>.
- [36] I. Zalila-Kolsi, D. Dhieb, H. A. Osman, and H. Mekideche, “The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions,” *Biology (Basel)*, vol. 14, no. 3, 2025, doi: 10.3390/biology14030251.
- [37] I. Cassol, M. Ibañez, and J. P. Bustamante, “Key features and guidelines for the application of microbial alpha diversity metrics,” *Sci. Rep.*, vol. 15, no. 1, pp. 1–13, 2025, doi: 10.1038/s41598-024-77864-y.

- [38] Z. Li *et al.*, “Differences in Alpha Diversity of Gut Microbiota in Neurological Diseases,” *Front. Neurosci.*, vol. 16, no. June, pp. 1–13, 2022, doi: 10.3389/fnins.2022.879318.
- [39] E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” *G. Ital. Cardiol.*, vol. 61, pp. 759–767, 1990, doi: 10.1016/0092-8674(90)90186-i.
- [40] B. Duan *et al.*, *Gastrointestinal cancers*. Brisbane, Australia: Exon Publications, 2022. doi: <https://doi.org/10.36255/exon-publications-gastrointestinal-cancers>.
- [41] E. Weledji, “The Etiology and Pathogenesis of Colorectal Cancer,” *Rem. Publ. LLC*, vol. 9, no. 2046, pp. 1–7, 2024.
- [42] I. Khan, “Understanding and Targeting the Colon Cancer Pathogenesis: A Molecular Perspective,” *Brazilian J. Pharm. Sci.*, vol. 58, pp. 1–14, 2022, doi: 10.1590/s2175-97902022e20354.
- [43] A. Malki, R. A. Elruz, I. Gupta, A. Allouch, S. Vranic, and A. E. Al Moustafa, “Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements,” *Int. J. Mol. Sci.*, vol. 22, no. 1, pp. 1–24, 2021, doi: 10.3390/ijms22010130.
- [44] S. H. Wong and J. Yu, “Gut microbiota in colorectal cancer: mechanisms of action and clinical applications,” *Nat. Rev. Gastroenterol. Hepatol.*, vol. 16, no. 11, pp. 690–704, 2019, doi: 10.1038/s41575-019-0209-8.
- [45] E. Saus, S. Iraola-Guzmán, J. R. Willis, A. Brunet-Vega, and T. Gabaldón, “Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential,” *Mol. Aspects Med.*, vol. 69, no. May, pp. 93–106, 2019, doi: 10.1016/j.mam.2019.05.001.
- [46] C. M. Dejea *et al.*, “Microbiota organization is a distinct feature of proximal colorectal cancers,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 111, no. 51, pp. 18321–18326, 2014, doi: 10.1073/pnas.1406199111.
- [47] K. Hou *et al.*, “Microbiota in health and diseases,” *Signal Transduct. Target. Ther.*, vol. 7, no. 1, 2022, doi: 10.1038/s41392-022-00974-4.

- [48] L. Ren, J. Ye, B. Zhao, J. Sun, P. Cao, and Y. Yang, “The Role of Intestinal Microbiota in Colorectal Cancer,” *Front. Pharmacol.*, vol. 12, no. April, pp. 1–9, 2021, doi: 10.3389/fphar.2021.674807.
- [49] K. D. Seely, A. D. Morgan, L. D. Hagenstein, G. M. Florey, and J. M. Small, “Bacterial Involvement in Progression and Metastasis of Colorectal Neoplasia,” *Cancers (Basel)*, vol. 14, no. 4, 2022, doi: 10.3390/cancers14041019.
- [50] S. Bullman *et al.*, “Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer,” vol. 358, no. 6369, pp. 1443–1448, 2018, doi: 10.1126/science.aal5240.Analysis.
- [51] R. I. Ayabe and M. G. White, “Metastasis and the Microbiome: The Impact of Bacteria in Disseminated Colorectal Cancer,” *Front. Biosci. - Landmark*, vol. 29, no. 4, 2024, doi: 10.31083/j.fbl2904152.
- [52] T. Therapy, “Colorectal cancer-derived extracellular vesicles induce liver premetastatic immunosuppressive niche formation to promote tumor early liver metastasis,” no. February, 2023, doi: 10.1038/s41392-023-01384-w.
- [53] K. T. Yeung and J. Yang, “Epithelial – mesenchymal transition in tumor metastasis,” vol. 11, pp. 28–39, 2017, doi: 10.1002/1878-0261.12017.
- [54] S. Lamouille, J. Xu, and R. Derynck, “Molecular mechanisms of epithelial-mesenchymal transition,” *Nat Rev Mol Cell Biol*, vol. 15, pp. 178–196, 2014, doi: 10.1038/nrm3758.
- [55] Y. Zhang *et al.*, “*Fusobacterium nucleatum* promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF- κ B/ICAM1 axis,” *Gut Microbes*, vol. 14, no. 1. 2022. doi: 10.1080/19490976.2022.2038852.
- [56] L. Sánchez-Alcoholado *et al.*, “The role of the gut microbiome in colorectal cancer development and therapy response,” *Cancers (Basel)*, vol. 12, no. 6, pp. 1–29, 2020, doi: 10.3390/cancers12061406.
- [57] H. Sung *et al.*, “Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data,” *Lancet Oncol.*, vol.

- 26, no. 1, pp. 51–63, 2025, doi: 10.1016/S1470-2045(24)00600-4.
- [58] A. Lewandowska, G. Rudzki, T. Lewandowski, A. Strykowska-Góra, and S. Rudzki, “Title: Risk Factors for the Diagnosis of Colorectal Cancer,” *Cancer Control*, vol. 29, pp. 1–15, 2022, doi: 10.1177/10732748211056692.
 - [59] L. Nguyen and S. Shanmugan, “A Review Article: The Relationship Between Obesity and Colorectal Cancer,” *Curr. Diab. Rep.*, vol. 25, no. 1, 2025, doi: 10.1007/s11892-024-01556-0.
 - [60] M. I. Mohammed Ilyas, “Epidemiology of Stage IV Colorectal Cancer: Trends in the Incidence, Prevalence, Age Distribution, and Impact on Life Span,” *Clin. Colon Rectal Surg.*, vol. 37, no. 2, pp. 57–61, 2024, doi: 10.1055/s-0043-1761447.
 - [61] H. Rumpold *et al.*, “Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis,” *BMC Cancer*, vol. 20, no. 1, pp. 1–9, 2020, doi: 10.1186/s12885-020-07656-w.
 - [62] N. Darnindro *et al.*, “Differences in diversity and composition of mucosa-associated colonic microbiota in colorectal cancer and non-colorectal cancer in Indonesia,” *World J. Gastroenterol.*, vol. 31, no. 7, pp. 1–17, 2025, doi: 10.3748/wjg.v31.i7.100051.
 - [63] G. Singh, Z. Chaudhry, A. Boyadzhyan, K. Sasaninia, and V. Rai, “Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives,” *Explor. Target. Anti-tumor Ther.*, vol. 6, pp. 1–22, 2025, doi: 10.37349/etat.2025.1002329.
 - [64] Y. L. Liu and J. Liu, “Gut microbiota plays a key role in the development of colorectal cancer,” *World J. Gastroenterol.*, vol. 31, no. 14, pp. 1–5, 2025, doi: 10.3748/wjg.v31.i14.105420.
 - [65] J. Queen *et al.*, “Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin,” *npj Biofilms Microbiomes*, vol. 11, no. 1, 2025, doi: 10.1038/s41522-025-00717-7.
 - [66] C. Sun *et al.*, “The role of Fusobacterium nucleatum in colorectal cancer : from

- carcinogenesis to clinical management,” *Chronic Dis. Transl. Med.*, vol. 5, no. 3, pp. 178–187, 2019, doi: 10.1016/j.cdtm.2019.09.001.
- [67] Y. Li, “Gut bacteria , host immunity , and colorectal cancer : From pathogenesis to therapy,” pp. 1–14, 2024, doi: 10.1002/eji.202451022.
- [68] C. Xu *et al.*, “Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization,” *Gut Microbes*, vol. 13, no. 1, pp. 1–17, 2021, doi: 10.1080/19490976.2021.1980347.
- [69] C. Jian, W. Yinhang, Z. Jing, Q. Zhanbo, W. Zefeng, and H. Shuwen, “Escherichia coli on colorectal cancer: A two-edged sword,” *Microb. Biotechnol.*, vol. 17, no. 10, pp. 1–18, 2024, doi: 10.1111/1751-7915.70029.
- [70] R. Kumar *et al.*, *Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development*, vol. 13, no. 7. 2017. doi: 10.1371/journal.ppat.1006440.
- [71] S. C. Tortora *et al.*, “Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences,” *World J Gastrointest Oncol*, vol. 14, no. 2, pp. 375–396, 2022, doi: 10.4251/wjgo.v14.i2.375.
- [72] S. Ebrahimzadeh *et al.*, “Colorectal cancer treatment using bacteria: focus on molecular mechanisms,” *BMC Microbiol.*, vol. 21, no. 1, pp. 1–12, 2021, doi: 10.1186/s12866-021-02274-3.
- [73] C. H. Lo *et al.*, “Enrichment of Prevotella intermedia in human colorectal cancer and its additive effects with Fusobacterium nucleatum on the malignant transformation of colorectal adenomas,” *J. Biomed. Sci.*, vol. 29, no. 1, pp. 1–18, 2022, doi: 10.1186/s12929-022-00869-0.
- [74] B. P. Wibowo, H. Kalim, H. Khotimah, and H. Sujuti, “The Effect of Salmonella AvrA Infection on Colon Cancer : An in-silico Study,” vol. 24, pp. 163–170, 2023, doi: 10.31557/APJCP.2023.24.1.163.
- [75] P. Wei *et al.*, “Microbiota in colorectal cancer related to liver metastasis,” *Chinese J. Cancer Res.*, vol. 36, no. 1, pp. 17–24, 2024, doi: 10.21147/j.issn.1000-9604.2024.01.02.

- [76] Z. He *et al.*, “Campylobacter jejuni-derived cytolethal distending toxin promotes colorectal cancer metastasis,” *Cell Host Microbe*, vol. 32, no. 12, pp. 2080–2091.e6, 2024, doi: 10.1016/j.chom.2024.11.006.
- [77] X. Long *et al.*, “Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity,” *Nat. Microbiol.*, vol. 4, no. 12, pp. 2319–2330, 2019, doi: 10.1038/s41564-019-0541-3.
- [78] M. W. Dougherty and C. Jobin, “Intestinal bacteria and colorectal cancer: etiology and treatment,” *Gut Microbes*, vol. 15, no. 1, pp. 1–27, 2023, doi: 10.1080/19490976.2023.2185028.
- [79] P. Zhou *et al.*, “Differences in tissue-associated bacteria between metastatic and non-metastatic colorectal cancer,” *Front. Microbiol.*, vol. 14, no. June, pp. 1–11, 2023, doi: 10.3389/fmicb.2023.1133607.
- [80] C. Crowley, A. Selvaraj, A. Hariharan, C. M. Healy, and G. P. Moran, “Fusobacterium nucleatum subsp. polymorphum recovered from malignant and potentially malignant oral disease exhibit heterogeneity in adhesion phenotypes and adhesin gene copy number, shaped by inter-subspecies horizontal gene transfer and recombination-der,” *Microb. Genomics*, vol. 10, no. 3, pp. 1–16, 2024, doi: 10.1099/mgen.0.001217.
- [81] Z. Zhou, J. Chen, H. Yao, and H. Hu, “Fusobacterium and colorectal cancer,” *Front. Oncol.*, vol. 8, no. OCT, pp. 1–11, 2018, doi: 10.3389/fonc.2018.00371.
- [82] W. Zheng, Y. Wang, H. Sun, S. Bao, S. Ge, and C. Quan, “The role of Fusobacterium nucleatum in macrophage M2 polarization and NF-κB pathway activation in colorectal cancer,” *Frontiers in Immunology*, vol. 16, 2025, doi: 10.3389/fimmu.2025.1549564.
- [83] J. Lu, W. Wei, and D. Zheng, “Fusobacterium nucleatum in Colorectal Cancer: Ally Mechanism and Targeted Therapy Strategies,” *Research*, vol. 8, pp. 1–6, 2025, doi: 10.34133/research.0640.
- [84] K. Liu *et al.*, “The Role of Fecal Fusobacterium nucleatum and pks+Escherichia coli as Early Diagnostic Markers of Colorectal Cancer,” *Dis. Markers*, vol.

2021, 2021, doi: 10.1155/2021/1171239.

- [85] Q. Deng *et al.*, “Streptococcus bovis contributes to the development of colorectal cancer via recruiting CD11b+TLR-4+Cells,” *Med. Sci. Monit.*, vol. 26, pp. 1–9, 2020, doi: 10.12659/MSM.921886.
- [86] A. Abugroun, R. Zughul, M. Tawadrous, and M. Rodriguez, “Group G Streptococcus Infective Endocarditis in Association With Colon Cancer,” *Cardiol. Res.*, vol. 9, no. 1, pp. 59–62, 2018, doi: 10.14740/cr653w.
- [87] P. Abedi Elkhichi *et al.*, “Prevalence of Campylobacter Species, Helicobacter pylori, Human Papillomavirus, and JC Polyomavirus in Patients with Colorectal Cancer in Iran,” *Arch. Clin. Infect. Dis.*, vol. 19, no. 3, 2024, doi: 10.5812/ARCHCID-132362.
- [88] K. Khan *et al.*, “Identification of Therapeutic Targets in an Emerging Gastrointestinal Pathogen Campylobacter ureolyticus and Possible Intervention through Natural Products,” *Antibiotics*, vol. 11, no. 5, pp. 1–18, 2022, doi: 10.3390/antibiotics11050680.
- [89] Y. C. Chen *et al.*, “Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer,” *Front. Oncol.*, vol. 12, no. September, pp. 1–13, 2022, doi: 10.3389/fonc.2022.955313.
- [90] C. Herløv, S. Sloth, and L. P. Andersen, “Colorectal Cancer and Campylobacter rectus, C. showae and C. concisus,” *EC Microbiol.*, vol. 7, pp. 39–44, 2022, doi: 10.1201/9781003524489-26.
- [91] G. Tract, “The Impact and Mechanism of Action of Peptostreptococcus anaerobius on Chemotherapy Resistance in Human Colorectal Cancer,” vol. 2024, 2024, doi: 10.5152/tjg.2024.24221.
- [92] Y. Liu *et al.*, “Gram-negative intratumoral bacteria mediate lymph node metastasis through LPS-TLR4/MAPK signaling pathway in cervical cancer,” *J. Infect.*, vol. 91, no. 2, p. 106532, 2025, doi: 10.1016/j.jinf.2025.106532.
- [93] S. Xia, L. Ma, H. Li, Y. Li, and L. Yu, “Prevalence of enterotoxigenic Bacteroides fragilis in patients with colorectal cancer: a systematic review and

- meta-analysis,” *Front. Cell. Infect. Microbiol.*, vol. 15, no. March, pp. 1–9, 2025, doi: 10.3389/fcimb.2025.1525609.
- [94] X. Ding *et al.*, “*Bacteroides fragilis* promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity,” *Cell Host Microbe*, vol. 33, no. 6, pp. 941–956.e10, 2025, doi: 10.1016/j.chom.2025.05.004.
- [95] V. Stévenin *et al.*, “Multi-omics analyses of cancer-linked clinical salmonellae reveal bacterial-induced host metabolic shift and mTOR-dependent cell transformation,” *Cell Rep.*, vol. 43, no. 11, 2024, doi: 10.1016/j.celrep.2024.114931.
- [96] J. Sun, “Impact of bacterial infection and intestinal microbiome on colorectal cancer development,” *Chin. Med. J. (Engl.)*, vol. 135, no. 4, pp. 400–408, 2022, doi: 10.1097/CM9.0000000000001979.
- [97] L. Zhao *et al.*, “*Parvimonas micra* promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients,” *Oncogene*, vol. 41, no. 36, pp. 4200–4210, 2022, doi: 10.1038/s41388-022-02395-7.

Lampiran

Tabel 1. Gambaran mikrobiota pada seluruh populasi

Genus	Abundance (OTUs)	Relative Abundance (%)
Escherichia	12074	23.4
Fusobacterium	9271	18.0
Streptococcus	3263	6.3
Klebsiella	2442	4.7
Prevotella	2418	4.7
Salmonella	2127	4.1
Gemella	1937	3.8
Vescimonas	1860	3.6
Campylobacter	1565	3.0
Peptostreptococcus	1438	2.8
Bacteroides	1236	2.4
Parvimonas	1079	2.1
Faecalibacterium	1034	2.0
Clostridioides	478	0.9
Enterocloster	452	0.9
Mediterraneibacter	448	0.9
Morganella	422	0.8
Dialister	363	0.7
Citrobacter	361	0.7
Clostridium	354	0.7
Enterobacter	345	0.7
Lachnoclostridium	344	0.7
Simiaoa	331	0.6
Flavonifractor	282	0.6
Coprococcus	278	0.5
Enterococcus	276	0.5
Selenomonas	272	0.5
Hungatella	267	0.5
Blautia	250	0.5
Solibaculum	245	0.5
Unknown	237	0.5
Filifactor	195	0.4

Roseburia	187	0.4
Christensenella	164	0.3
Yersinia	158	0.3
Shigella	157	0.3
Dorea	145	0.3
Vibrio	141	0.3
Ruminococcus	128	0.3
Emergencia	118	0.2
Ruthenibacterium	117	0.2
Qiania	116	0.2
Serratia	110	0.2
Phascolarctobacterium	109	0.2
Eisenbergiella	108	0.2
Lachnoanaerobaculum	92	0.2
Erwinia	82	0.2
Granulicatella	82	0.2
Peptoniphilus	78	0.2
Segatella	78	0.2
Anaerotruncus	76	0.2
Dickeya	74	0.1
Kosakonia	62	0.1
Anaerococcus	61	0.1
Intestinimonas	60	0.1
Providencia	58	0.1
Haemophilus	57	0.1
Thermocaproicibacter	56	0.1
Megasphaera	52	0.1
Xanthomonas	51	0.1
Terrisporobacter	49	0.1
Oscillibacter	49	0.1
Ligilactobacillus	48	0.1
Candidatus Annandia	46	0.1
Chakrabartyella	46	0.1
Caloramator	43	0.1
Paludihabitans	42	0.1
Sodalis	38	0.1
Proteus	33	0.1

Pantoea	33	0.1
Pseudomonas	32	0.1
Porphyromonas	31	0.1
Flintibacter	30	0.1
Heliorestis	30	0.1
Odoribacter	29	0.1
Selenobaculum	26	0.1
Candidatus Epulonipiscium	24	0.1
Lawsonibacter	22	0.0
Alicyclobacillus	22	0.0
Agathobacter	19	0.0
Aeromonas	19	0.0
Stomatobaculum	19	0.0
Xenorhabdus	18	0.0
Bacillus	16	0.0
Lentisphaera	16	0.0
Edwardsiella	15	0.0
Desulfovibrio	14	0.0
Anaerobutyricum	13	0.0
Pseudoalteromonas	12	0.0
Alkalibacter	10	0.0

Tabel 2. Gambaran mikrobiota pada pasien kanker kolorektal metastasis

genus	Abundance (OTUs)	Relative Abundance (%)
Escherichia	11071	26.48
Fusobacterium	7803	18.66
Streptococcus	3025	7.23
Klebsiella	2346	5.61
Prevotella	2268	5.42
Salmonella	1956	4.68
Vescimonas	1860	4.45
Gemella	1455	3.48
Faecalibacterium	925	2.21
Peptostreptococcus	660	1.58
Campylobacter	592	1.42
Bacteroides	461	1.10
Morganella	422	1.01
Enterocloster	399	0.95
Parvimonas	378	0.90
Citrobacter	361	0.86
Enterobacter	345	0.83
Simiaoa	299	0.72
Coprococcus	252	0.60
Dialister	245	0.59
Solibaculum	245	0.59
Clostridioides	244	0.58
Blautia	178	0.43
Unknown	172	0.41
Filifactor	166	0.40
Selenomonas	160	0.38
Yersinia	158	0.38
Shigella	157	0.38
Clostridium	148	0.35
Dorea	145	0.35
Vibrio	141	0.34
Mediterraneibacter	135	0.32
Christensenella	134	0.32
Ruminococcus	128	0.31
Roseburia	128	0.31

Ruthenibacterium	117	0.28
Serratia	110	0.26
Hungatella	109	0.26
Eisenbergiella	108	0.26
Phascolarctobacterium	96	0.23
Erwinia	82	0.20
Flavonifractor	82	0.20
Peptoniphilus	78	0.19
Segatella	78	0.19
Dickeya	74	0.18
Kosakonia	62	0.15
Providencia	58	0.14
Haemophilus	57	0.14
Thermocaproicibacter	56	0.13
Lachnoclostridium	54	0.13
Megasphaera	52	0.12
Xanthomonas	51	0.12
Granulicatella	50	0.12
Intestinimonas	47	0.11
Candidatus Annandia	46	0.11
Chakrabartyella	46	0.11
Caloramator	43	0.10
Paludihabitans	42	0.10
Sodalis	38	0.09
Pantoea	33	0.08
Proteus	33	0.08
Pseudomonas	32	0.08
Anaerotruncus	31	0.07
Porphyromonas	31	0.07
Heliorestis	30	0.07
Oscillibacter	29	0.07
Odoribacter	29	0.07
Ligilactobacillus	27	0.06
Selenobaculum	26	0.06
Lachnoanaerobaculum	25	0.06
Qiania	24	0.06
Candidatus Epulonipiscium	24	0.06

Alicyclobacillus	22	0.05
Lawsonibacter	22	0.05
Emergencia	21	0.05
Stomatobaculum	19	0.05
Aeromonas	19	0.05
Agathobacter	19	0.05
Xenorhabdus	18	0.04
Lentisphaera	16	0.04
Flintibacter	16	0.04
Edwardsiella	15	0.04
Desulfovibrio	14	0.03
Terrisporobacter	14	0.03
Anaerobutyricum	13	0.03
Pseudoalteromonas	12	0.03
Anaerococcus	0	0.00

Tabel 3. Gambaran mikrobiota pada pasien kanker kolorektal tanpa metastasis

Genus	Abundance (OTUs)	Relative Abundance (%)
Fusobacterium	1468	15.05
Escherichia	1003	10.28
Campylobacter	973	9.98
Peptostreptococcus	778	7.98
Bacteroides	775	7.95
Parvimonas	701	7.19
Gemella	482	4.94
Mediterraneibacter	313	3.21
Lachnoclostridium	290	2.97
Enterococcus	276	2.83
Streptococcus	238	2.44
Clostridioides	234	2.40
Clostridium	206	2.11
Flavonifractor	200	2.05
Salmonella	171	1.75
Hungatella	158	1.62
Prevotella	150	1.54
Dialister	118	1.21
Selenomonas	112	1.15
Faecalibacterium	109	1.12
Emergencia	97	0.99
Klebsiella	96	0.98
Qiana	92	0.94
Blautia	72	0.74
Lachnoanaerobaculum	67	0.69
Unknown	65	0.67
Anaerococcus	61	0.63
Roseburia	59	0.60
Enterocloster	53	0.54
Anaerotruncus	45	0.46
Terrisporobacter	35	0.36
Granulicatella	32	0.33
Simiaoa	32	0.33
Christensenella	30	0.31
Filifactor	29	0.30

Coprococcus	26	0.27
Ligilactobacillus	21	0.22
Oscillibacter	20	0.21
Bacillus	16	0.16
Flintibacter	14	0.14
Intestinimonas	13	0.13
Phascolarctobacterium	13	0.13
Alkalibacter	10	0.10
